VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer

• DOI: 10.1038/srep02868
• Publication Date: 2013-10-08T09:02:41Z
• Authors: Janelle C. Arthur; Raad Z. Gharaibeh; Joshua M. Uronis; Ernesto Perez-Cha...; Wei Sha; Sarah Tomkovich; Marcus Mühlbauer; Anthony A. Fodor; Christian Jobin
• Keywords: Mice, Knockout; 0303 health sciences; Microbiota; Probiotics; Colitis; Article; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; Cell Transformation, Neoplastic; Animals; Intestinal Mucosa; Colorectal Neoplasms

Although probiotics have shown success in preventing the development of experimental colitis-associated colorectal cancer (CRC), beneficial effects interventional treatment are relatively unknown. Here we show that with VSL#3 probiotic alters luminal and mucosally-adherent microbiota, but does not protect against inflammation or tumorigenesis azoxymethane (AOM)/Il10−/− mouse model CRC. (109 CFU/animal/day) significantly enhanced tumor penetrance, multiplicity, histologic dysplasia scores adenocarcinoma invasion relative to VSL#3-untreated mice. Illumina 16S sequencing demonstrated decreased (16-fold) abundance a bacterial taxon assigned genus Clostridium microbiota. Mediation analysis by linear models suggested this was contributing factor increased VSL#3-fed We conclude therapy can alter microbial community composition enhance AOM/Il10−/− model.